Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Revenue (2019 - 2025)

Historic Revenue for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to $22.5 million.

  • Eton Pharmaceuticals' Revenue rose 11754.17% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year decrease of 410.38%. This contributed to the annual value of $39.0 million for FY2024, which is 2328.87% up from last year.
  • Per Eton Pharmaceuticals' latest filing, its Revenue stood at $22.5 million for Q3 2025, which was up 11754.17% from $18.9 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Revenue ranged from a high of $29.8 million in Q4 2023 and a low of $775000.0 during Q3 2021
  • Its 5-year average for Revenue is $9.3 million, with a median of $8.0 million in 2024.
  • In the last 5 years, Eton Pharmaceuticals' Revenue skyrocketed by 20320000.0% in 2021 and then plummeted by 8170.97% in 2022.
  • Over the past 5 years, Eton Pharmaceuticals' Revenue (Quarter) stood at $6.1 million in 2021, then skyrocketed by 39.47% to $8.5 million in 2022, then soared by 250.69% to $29.8 million in 2023, then tumbled by 60.92% to $11.6 million in 2024, then surged by 92.83% to $22.5 million in 2025.
  • Its last three reported values are $22.5 million in Q3 2025, $18.9 million for Q2 2025, and $1.8 million during Q1 2025.